Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression.

Vagus nerve stimulation (VNS) is an approved neurostimulation therapy. The purpose of the method is to treat patients with therapy-resistant depression (TRD). VNS exhibits antidepressive and stabilizing effects. This method is particularly useful as a long-term treatment, in which up to two-thirds of patients respond. The vagus nerve stimulator is positioned on the left vagus nerve during a surgical procedure and is activated telemetrically by a wand connected to a handheld computerized device. The treating physician can perform various adjustments of the vagus nerve stimulator during in-office visits (e.g., by modifying stimulation intensity or stimulation frequency) to achieve maximum therapeutic effects with low side effects. Set-up of the device usually takes several months. Typical side effects include wound infection, temporary salivation, coughing, paralysis of the vocal cords, bradycardia, or even asystole. The patient can stop the VNS by placing a magnet over the generator. The current protocol describes delivery of the specific stimulation tool and methods for adjusting the tuning parameters to achieve the best remission rates in patients with TRD.

[1]  Jejo D. Koola,et al.  Serial Vagus Nerve Stimulation Functional MRI in Treatment-Resistant Depression , 2007, Neuropsychopharmacology.

[2]  Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. , 2007, The American journal of psychiatry.

[3]  W. Maier,et al.  Two-Year Outcome of Vagus Nerve Stimulation in Treatment-Resistant Depression , 2010, Journal of clinical psychopharmacology.

[4]  Alan Frazer,et al.  Vagal Nerve Stimulation for Treatment-Resistant Depression , 2017, Neurotherapeutics.

[5]  Gregor Hasler,et al.  Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders , 2018, Front. Psychiatry.

[6]  P. Tak,et al.  Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis , 2017, Journal of internal medicine.

[7]  W. Sperling,et al.  Efficacy and long-term tuning parameters of vagus nerve stimulation in long-term treated depressive patients , 2017, Journal of Clinical Neuroscience.

[8]  D. Nutt,et al.  The hidden third: improving outcome in treatment-resistant depression , 2012, Journal of psychopharmacology.

[9]  M. Strippoli,et al.  Prospective associations of depression subtypes with cardio-metabolic risk factors in the general population , 2017, Molecular Psychiatry.

[10]  H. Kraemer,et al.  Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder , 2006, Neuropsychopharmacology.

[11]  M. Strippoli,et al.  Prevalence and correlates of DSM-5 major depressive and related disorders in the community , 2017, Psychiatry Research.

[12]  Robert Goodman,et al.  Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study∗ ∗ See accompanying Editorial, in this issue. , 2000, Biological Psychiatry.

[13]  Cedric L. Williams,et al.  The effects of peripheral vagal nerve stimulation at a memory-modulating intensity on norepinephrine output in the basolateral amygdala. , 2004, Behavioral neuroscience.

[14]  A. Nierenberg,et al.  Vagus Nerve Stimulation: 2-Year Outcomes for Bipolar Versus Unipolar Treatment-Resistant Depression , 2008, Biological Psychiatry.

[15]  R. Mojtabai.  Nonremission and time to remission among remitters in major depressive disorder: Revisiting STAR*D , 2017, Depression and anxiety.

[16]  W. Maier,et al.  Vagus nerve stimulation for depression: efficacy and safety in a European study , 2008, Psychological Medicine.

[17]  M. Mintun,et al.  Association of Cerebral Metabolic Activity Changes with Vagus Nerve Stimulation Antidepressant Response in Treatment-Resistant Depression , 2013, Brain Stimulation.

[18]  B. Leonard,et al.  Therapy-Resistant Depression , 1988, British Journal of Psychiatry.

[19]  O. Devinsky,et al.  Efficacy of vagus nerve stimulation over time: Review of 65 consecutive patients with treatment-resistant epilepsy treated with VNS >10years , 2011, Epilepsy & Behavior.

[20]  T. Connor,et al.  The Effects of Vagus Nerve Stimulation on Pro- and Anti-Inflammatory Cytokines in Humans: A Preliminary Report , 2005, Neuroimmunomodulation.

[21]  T. Schlaepfer,et al.  Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex , 2011, Psychiatry Research: Neuroimaging.

[22]  A. Rush,et al.  Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. , 2005, The Journal of clinical psychiatry.

[23]  A. Frazer,et al.  Serotonergic and Noradrenergic Pathways Are Required for the Anxiolytic-like and Antidepressant-like Behavioral Effects of Repeated Vagal Nerve Stimulation in Rats , 2011, Biological Psychiatry.

[24]  Cole A. Giller,et al.  Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression: Efficacy, Side Effects, and Predictors of Outcome , 2001, Neuropsychopharmacology.

[25]  Yash Jobanputra,et al.  Devices and interventions for the prevention of adverse outcomes of tachycardia on heart failure , 2018, Heart Failure Reviews.

[26]  P. Hay,et al.  Acupuncture for depression. , 2005, The Cochrane database of systematic reviews.

[27]  D. Dougherty,et al.  A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. , 2017, The American journal of psychiatry.

[28]  F. Gaita,et al.  Screening of depression in cardiology: A study on 617 cardiovascular patients. , 2017, International journal of cardiology.

[29]  Z. Bai,et al.  Light therapy for older patients with non-seasonal depression: A systematic review and meta-analysis. , 2018, Journal of affective disorders.

[30]  I. Tonhajzerova,et al.  Which psychological, psychophysiological, and anthropometric factors are connected with life events, depression, and quality of life in patients with cardiovascular disease , 2017, Neuropsychiatric disease and treatment.

[31]  T. Bschor.  Therapy-resistant depression , 2010, Expert review of neurotherapeutics.

[32]  S. Riedel-Heller,et al.  Current major depressive syndrome measured with the Patient Health Questionnaire-9 (PHQ-9) and the Composite International Diagnostic Interview (CIDI): results from a cross-sectional population-based study of adults in Germany , 2015, BMC Psychiatry.

[33]  M. Husain,et al.  Concomitant Use of Vagus Nerve Stimulation and Electroconvulsive Therapy for Treatment-resistant Depression , 2006, The journal of ECT.

[34]  T. Kleinjung,et al.  Neuromodulation for tinnitus treatment: an overview of invasive and non-invasive techniques , 2018, Journal of Zhejiang University-SCIENCE B.

[35]  A. Rush,et al.  A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression , 2013, Medical devices.

[36]  P. Vajkoczy,et al.  Implantation of a new Vagus Nerve Stimulation (VNS) Therapy® generator, AspireSR®: considerations and recommendations during implantation and replacement surgery—comparison to a traditional system , 2015, Acta Neurochirurgica.

[37]  Barry R. Rittberg,et al.  A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression , 2005, Biological Psychiatry.

[38]  D. Kupfer,et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.

[39]  P. Falkai,et al.  Vagus nerve stimulation in psychiatry: a systematic review of the available evidence , 2016, Journal of Neural Transmission.

[40]  J. Lorberbaum,et al.  A review of functional neuroimaging studies of vagus nerve stimulation (VNS). , 2003, Journal of psychiatric research.

[41]  Mustafa M. Husain,et al.  Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial , 2005, Biological Psychiatry.

[42]  C. Barba,et al.  Vagus nerve stimulation: Surgical technique of implantation and revision and related morbidity , 2017, Epilepsia.

[43]  M. Trivedi,et al.  The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. , 1999, The Journal of clinical psychiatry.

[44]  Barry R. Rittberg,et al.  Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study , 2005, Biological Psychiatry.

[45]  Douglas C. Smith,et al.  Increased extracellular concentrations of norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat , 2006, Brain Research.

[46]  José V. Pardo,et al.  Chronic vagus nerve stimulation for treatment-resistant depression decreases resting ventromedial prefrontal glucose metabolism , 2008, NeuroImage.

[47]  J. Rutka,et al.  Revision of vagal nerve stimulation (VNS) electrodes: review and report on use of ultra-sharp monopolar tip , 2010, Child's Nervous System.

[48]  N. Matsuki,et al.  Vagus nerve stimulation enhances perforant path-CA3 synaptic transmission via the activation of β-adrenergic receptors and the locus coeruleus. , 2012, The international journal of neuropsychopharmacology.

[49]  J. Michalak,et al.  The treatment of chronic depression with cognitive behavioral analysis system of psychotherapy: a systematic review and meta‐analysis of randomized‐controlled clinical trials , 2016, Brain and behavior.

[50]  V. Sinniger,et al.  Anti‐inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation , 2016, The Journal of physiology.

[51]  S. L. Stebel,et al.  The role of vagus nerve stimulation in refractory epilepsy , 2016, Arquivos de Neuro-Psiquiatria.

[52]  J. Kornhuber,et al.  Facilitative effects of VNS on the motor threshold: implications for its antidepressive mode of action? , 2013, Journal of Neural Transmission.

[53]  H. Müller,et al.  Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use , 2018, Front. Neurosci..

[54]  F. Alzoubi,et al.  The vagal nerve stimulation outcome, and laryngeal effect: Otolaryngologists roles and perspective. , 2017, American journal of otolaryngology.

[55]  C. Cusin,et al.  Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS , 2012, Biology of Mood & Anxiety Disorders.